The proof-of-concept demonstrated several benefits:
- We could now get an early warning of water quality drift. Instead of waiting for the lab, the system would alert if conditions were trending poorly, essentially implementing continuous process verification for the water loop.
- It reduced uncertainty – if the model stayed green, QA and operations had more confidence to continue as normal. Eventually this can enable real-time batch release on the water quality paramater with fewer lab tests.
- The data analysis also led to process knowledge gains. For example, seeing how much a slight temperature change affected microbial risk prompted the team to adjust some control settings to keep the temperature more stable, thereby improving the process.
By the end of the POC, we had a working prototype of a predictive QC monitoring tool. We documented everything (data sources, model version, performance metrics) because we knew if this were to move to production, we’d need to validate it. The response from stakeholders was enthusiastic – they could clearly see how this would enhance quality assurance. An inspector or auditor could also appreciate that we were using modern tools to augment our quality system, not replace it: we still did daily samples until the model is fully validated, but we now had an extra layer of safety.
In a full implementation, we planned to integrate this with the existing SCADA system and send alerts via the operators’ interface – making it a seamless part of operations. We also discussed linking it to the deviation management process: e.g., if the model predicts a likely OOS, automatically create a notification or even a draft deviation record for QA to review, in line with SOPs, which is a step toward prescriptive analytics, where the system not only predicts but also triggers actions.
This case study underscores how a focused ML project can yield tangible benefits in pharma manufacturing. We took a familiar problem in water quality monitoring and solved it in a new way, made possible by the data that was already collected. The project took only a few months from start to finish and required no new hardware or costly infrastructure – just smarter use of existing resources.
Moving forward, the question became: how do we scale and deploy such solutions across other systems and sites? That’s where things like a solid data platform, model lifecycle management, and validation come into play.
In Part 3, we will shift from the nuts-and-bolts of this single project to a broader view of implementing AI solutions in a GxP-regulated organization. We’ll discuss the technical architecture (hint: leverage a data fabric) the validation and compliance considerations, and how to drive organizational change to support AI. Essentially, how to go from a successful pilot to a sustainable, value-driving AI capability across the company.
Stay tuned for Part 3, where we delve into deployment, scale-up, and the strategic aspects of pharma AI implementation.
Continue to part 3